Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Birmingham, AL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Florence, AL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Florence, AL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Mobile, AL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Anchorage, AK
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Anchorage, AK
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Tucson, AZ
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Fresno, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Fresno, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Loma Linda, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Long Beach, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Riverside, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
San Diego, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Sepulveda, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Sepulveda, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Hartford, CT
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Hartford, CT
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Bay Pines, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Brandon, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Brandon, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Clearwater, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Cocoa, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Cocoa, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Gainesville, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Kissimmee, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Orlando, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Winter Park, FL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Lawrenceville, GA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Belleville, IL
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Belleville, IL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Council Bluffs, IA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Wichita, KA
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Baltimore, MD
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Columbia, MD
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Columbia, MD
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Livonia, MI
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Livonia, MI
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Fridley, MN
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Fridley, MN
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Kansas City, MO
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Lincoln, NE
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Omaha, NE
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Buffalo, NY
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
North Syracuse, NY
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
North Syracuse, NY
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Charlotte, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Durham, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Elizabeth City, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Elizabeth City, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Statesville, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Statesville, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Wilmington, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Canton, OH
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Canton, OH
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Dayton, OH
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated:  10/9/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization
Status: Enrolling
Updated: 10/9/2017
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials